Duration of Pataday 0.7% Treatment
Pataday 0.7% (olopatadine hydrochloride 0.77%) should be used once daily for as long as you are exposed to allergens causing your symptoms, with no specific maximum duration limit established for allergic conjunctivitis.
Dosing Regimen
The 0.7% formulation is specifically designed for once-daily dosing with a 24-hour duration of action 1, 2. This represents a key advantage over lower concentration formulations:
- Olopatadine 0.77%: Once daily dosing
- Olopatadine 0.2%: Once daily dosing (but shorter duration than 0.77%)
- Olopatadine 0.1%: Twice daily dosing
Treatment Duration Approach
For seasonal allergic conjunctivitis:
- Continue daily use throughout the allergy season while exposed to triggering allergens (pollen, grass, ragweed, pet dander) 3
- Discontinue when allergen exposure ends or symptoms resolve
For perennial allergic conjunctivitis:
- May require ongoing daily use as long as allergen exposure continues
- No established maximum treatment duration in the literature
Clinical Evidence Supporting Extended Use
The medication demonstrates:
- Rapid onset of action (works within 3-7 minutes) 2
- Sustained 24-hour efficacy 1, 2
- Superior itch relief compared to vehicle and lower concentrations 1, 2
- Favorable safety profile with no identified safety concerns in clinical trials 1, 2
Important Caveats
When to reassess:
- If symptoms persist beyond 2-3 weeks despite treatment, patients should return for evaluation to rule out other causes of conjunctivitis 4
- The provided guidelines focus on viral/bacterial conjunctivitis rather than allergic conjunctivitis, so direct guideline support for duration is limited
Safety monitoring:
- Unlike topical corticosteroids (which require careful monitoring for IOP elevation and cataracts), antihistamine/mast cell stabilizers like olopatadine do not carry these risks 4
- No routine follow-up for IOP or other complications is required for olopatadine monotherapy
Practical approach:
- Use one drop in each affected eye once daily
- Time administration based on when maximum allergen exposure occurs
- Continue as needed for symptom control without arbitrary time limits